Pacific Eye Begins Clinical Trials

July 14, 2014

Dr. Mark Sherman and Tammy Lauinger recently attended an Investigators Meeting for the worldwide EyeGuard A&C Studies in San Francisco.  Pacific Eye has been selected as a study site for this research looking at methods investigating the treatment of both active and controlled non-infectious panuveitis.  Dr. Sherman has been designated the site’s Principal Investigator and Tammy Lauinger is the Coordinator of clinical research at Pacific Eye.  Dr. Sherman is fellowship trained in both corneal disease and uveitis. 

Uveitis refers to inflammation of the uveal tract, or middle layer of the eye.  This includes inflammation of the iris (the colored part of the eye) and its neighboring structures all the way to the back of the eye, or optic nerve.  Symptoms of uveitis include eye pain, decreased vision, sensitivity to light and redness.  While uveitis is not a common eye disease, its effects can be devastating.  Uveitis most commonly affects the young and middle-aged.  It can therefore have serious personal as well as socio-economic impact on the community. 

The EyeGuard Studies will examine the effectiveness of an investigational drug called “gevokizumab” for the control of the inflammatory attack on the eye in patients with non-infectious panuveitis.  Gevokizumab was developed and is manufactured by Xoma, a company located in Northern California devoted to the research and development of monoclonal antibody therapies. 

For more information contact Pacific Eye at (805) 545-8100 or visit us on the web at www.paceyemd.com

« Back to Press Releases Back to Top